Arbutus Biopharma Co. (NASDAQ:ABUS) Stock Position Cut by Corbin Capital Partners L.P.

Corbin Capital Partners L.P. lessened its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 682,487 shares of the biopharmaceutical company’s stock after selling 170,817 shares during the quarter. Arbutus Biopharma makes up 3.7% of Corbin Capital Partners L.P.’s holdings, making the stock its 5th biggest position. Corbin Capital Partners L.P.’s holdings in Arbutus Biopharma were worth $2,232,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in shares of Arbutus Biopharma in the 4th quarter valued at about $236,000. Charles Schwab Investment Management Inc. grew its holdings in Arbutus Biopharma by 218.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock valued at $4,667,000 after purchasing an additional 831,663 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Arbutus Biopharma in the third quarter valued at approximately $754,000. Barclays PLC raised its stake in shares of Arbutus Biopharma by 466.3% during the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock worth $1,047,000 after buying an additional 223,995 shares during the period. Finally, State Street Corp lifted its position in shares of Arbutus Biopharma by 50.2% during the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock valued at $16,967,000 after buying an additional 1,472,652 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ABUS shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, Arbutus Biopharma presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $3.31 on Friday. The stock has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.61. Arbutus Biopharma Co. has a one year low of $2.30 and a one year high of $4.73. The stock has a market capitalization of $627.22 million, a price-to-earnings ratio of -7.70 and a beta of 1.93.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.